Sub menu

 
 

Submissions received: Regulation of autologous stem cell therapies

Last updated

The TGA sought comments from interested parties on Regulation of autologous stem cell therapies, regarding whether the regulation applied to some autologous cells is appropriate, in a consultation that closed on 3 March 2015.

A total of 80 submissions were received. Of the submissions 14 from professional bodies, 12 from researchers, institutions or hospitals, 4 from industry groups, 4 from consumer groups, 20 from manufacturers, suppliers or health practitioners providing autologous stem cell therapies (businesses), 21 from patients and 5 from government bodies or other stakeholders. All submissions that were not marked as confidential are now available below in PDF format.

Consultation feedback

The TGA is currently considering all submissions that were received as part of this consultation. The TGA thanks those who took the time to make a submission and to make comments and suggestions.

The TGA is not able to approximate a timeframe for publication of the outcome of the consultation at this time.

Further information will be provided as it becomes available.

More information

Any questions relating to submissions should be directed to Dr Tony Manderson, Principal Adviser, Biological Science Section, Office of Scientific Evaluation by email to bloodandtissues@tga.gov.au or by telephone to 1800 678 799.

Submissions

A B C D E G I K M N O R S U

A

B

C

D

E

G

I

K

M

N

O

  • Consultation submission: Ocular Stem Cells Australia Group - Clinical Professor Stephanie Watson

R

S

U

Help us improve the Therapeutic Goods Administration site